Diabetes Type 2

Type 2 Diabetes and Medication Adherence: Where is the Disconnect?

Incretin drugs, which offer ease of use, very little hypoglycemia, and no weight gain (or even weight loss) seem to be an ideal therapy. But 80% to 90% of patients don’t stay on them. Why not?

Diabetes Type 2

Studies looking at add-on treatment with SGLT2 inhibitors show their effects on glycemic control to be roughly additive. Here, a concise look at clinical trial results plus guidance on renal dose adjustment.

For the 30% of people with T2DM who are unable to achieve target A1C values through intensification of injected insulin therapy, a new study suggests the answer may be "yes."

Empagliflozin is the third sodium-glucose cotransporter 2 inhibitor approved for use in the US. There is a lot to learn about this new class. Here, 5 of the many things you need to know.

Studies on the health benefits of tree nut consumption go back decades, and link many varieties with reduced risk for diabetes and improved glycemic control.

This patient's presenting symptom, in the context of his overall health, should prompt orders for which follow-up studies?

Premixed insulin--a basal and prandial product delivered in one injection--sounds like an ideal solution for patients who resist multidose insulin therapy. For some it is, but not for all. A case and the caveats, here.

There are 2 FDA-approved sodium-glucose contransporter-2 inhibitors available in the United States. Here, a concise review of advantages/disadvantages and considerations in patient selection.


Subscribe to Diabetes Type 2 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.